Description:

In patients with CKD, the decline in GFR reduces the clearance of insulin and many diabetes medications and raises the risk of hypoglycemia with insulin, sulfonylureas and glinides. GLP1 agonists have cardiovascular benefits, and SGLT2 inhibitors significantly decrease kidney and cardiovascular outcomes making them the class of choice for those with CKD. 

Targets for glycemic control should be individualized taking CKD into consideration, and glycemic control should be monitored with HbA1c, supplemented with SMBG or CGM when hypoglycemia is of concern. Multidisciplinary teamwork with collaboration between GP, endocrinologist and nephrologist is important for success.

This is a CME-CPD accredited activity.
Number of credits: 2

Description:

This course refreshes Primary Care Physicians' knowledge on T2D in recognition of their generalist skills, supporting them to become more comfortable with their critical role in addressing barriers to T2D treatment optimization, focusing on the role of GLP-1RAs as part of the current landscape of incretin therapies for T2D.

Developed in collaboration with Dr Abbas Raza (Pakistan), Dr Alvin Powers (USA), Dr David D'Alessio (USA), and Dr Boris Draznin (USA)

This is a CME-CPD accredited activity.
Number of credits: 1

Description:

This session addresses some of the implications of Metabesity, namely cardiovascular, renovascular, and glucometabolic dysfunction.

Developed in collaboration with Dr Mathew John, Dr Perla Carrillo, and Dr Anthonia Ogbera.

This is a CME-CPD accredited activity.
Number of credits: 1

Description:

This course explores the definitions of "metabolic syndrome" and "obesity" and will give you the tools to compare and contrast the definition of "obesity" in childhood and adolescence, and recognize the rationale for ethno-specific cutoffs. 

Developed in collaboration with Dr Hasan Aydın (Turkey).

This is a CME-CPD accredited activity.
Number of credits: 1

Description:

This course analyses the environmental factors driving obesity, identifies cues during development, plasticity, and determination of the adult phenotype, addresses the role of Endocrine Disruptive Chemicals and the central nervous system in obesity, and gives an insight into the different genetic causes of obesity.

Developed in collaboration with Dr Ankia Coetzee (South Africa).

This is a CME-CPD accredited activity.
Number of credits: 1

Description:

This course explores the advantages and limitations of different anthropometric indicators, analyses the the importance of assessing body composition in clinical practice and the concept of Normal Weight Obesity, and gives an insight into emerging concepts in obesity assessment.

Developed in collaboration with Dr Nitin Kapoor (India).

ISE-ISN Webinar

This is a CME-CPD accredited activity. 
Number of credits: 2

Description:

Increased morbidity and mortality from COVID-19 in patients with Diabetes Mellitus have been noted in those countries hardest hit by the pandemic. This webinar addresses this association and the optimal management of infected patients with Diabetes Mellitus, with an insight into the impact of COVID-19 on the kidney, association of kidney disease with outcomes and management of COVID-19 disease and considerations for the outpatient management of kidney disease patients in the setting of the COVID-19 pandemic.

ISE-ISN Webinar

This is a CME-CPD accredited activity. 
Number of credits: 2

Description:

Join Dr Peter Rossing and Dr Mark E Molitch in a conversation about the current management of diabetes in patients with kidney disease.

This is a CME-CPD accredited activity.
Number of credits: 1

Description:

This course will give you an insight into a profound and worldwide paradigm change in the treatment of Type 2 Diabetes and the latest cardiovascular and renal protective effects with Type 2 Diabetes medications.

This is a CME-CPD accredited activity.
Number of credits: 2

Description:

This interactive webinar series organized by the mdBriefCase Group has assembled a panel of diabetes experts to discuss new and emerging treatment options and their impact on individualized care.